Aquestive Therapeutics In... (AQST)
NASDAQ: AQST
· Real-Time Price · USD
4.71
0.76 (19.24%)
At close: Sep 04, 2025, 10:23 AM
19.24% (1D)
| Bid | 3.51 |
| Market Cap | 469.23M |
| Revenue (ttm) | 44.13M |
| Net Income (ttm) | -65.04M |
| EPS (ttm) | -0.69 |
| PE Ratio (ttm) | -6.82 |
| Forward PE | -6.84 |
| Analyst | Buy |
| Ask | 5.5 |
| Volume | 3,710,393 |
| Avg. Volume (20D) | 1,367,558 |
| Open | 4.29 |
| Previous Close | 3.95 |
| Day's Range | 4.24 - 4.88 |
| 52-Week Range | 2.12 - 5.80 |
| Beta | 1.99 |
About AQST
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AQST
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AQST stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Aquestive Therapeutics Inc. is scheduled to release its earnings on
Nov 3, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
-19.65%
Aquestive Therapeutics shares are trading lower af...
Unlock content with
Pro Subscription
6 months ago
+2.2%
Aquestive Therapeutics shares are trading lower after the company reported worse-than-expected Q4 financial results
2 months ago · seekingalpha.com
Aquestive Therapeutics: Updating The Anaphylm Timeline To ApprovalAnaphylm's FDA approval process is a major catalyst, with a PDUFA date set for January 31, 2026, and potential AdCom or partnership news ahead. Anaphylm offers a needle-free, orally delivered epinephr...
2 months ago · seekingalpha.com
Aquestive Therapeutics: Anaphylm Could Gain Significant Market ShareAquestive Therapeutics' Anaphylm offers a unique, non-injectable epinephrine solution for anaphylaxis, with NDA decision expected imminently. Anaphylm's advantages—wallet portability, rapid onset, and...